MRNA · News · 20260805N

Operating Expense Trends

Moderna, Inc. · 2026-08-05 · Importance 37 · Surprise 42

Moderna’s second-quarter 2026 earnings call emphasized cost reductions alongside pipeline investment. Management tightened its 2026 cost-of-sales and research-and-development guidance, although the digest did not provide revised dollar amounts. The cost-cutting program is intended to support revenue growth while the company advances flu, oncology, and rare-disease programs.

Key facts

• A Form 144 SEC filing on August 5, 2026 indicates a proposed sale of 499,246 shares of common stock with an aggregate market value of $28,956,268.00 resulting from a stock option exercise by an individual with a relationship to the issuer. source
• Quantinno Capital Management LP increased its stake in Moderna by 74.7% during the first quarter, now owning 168,077 shares worth approximately $8.5 million. source
• Cetera Investment Advisers owned 81,306 shares of Moderna after purchasing an additional 17,859 shares, representing a 28.1% increase and a $4.13 million stake. source